Literature DB >> 8930151

Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance.

Y A Kolesnikov1, S Jain, R Wilson, G W Pasternak.   

Abstract

Morphine injected s.c. in the tail is a potent analgesic in the tail-flick assay when the radiant heat source is focused directly over the injection site (ED50, 4.5 micrograms), but not if the radiant heat source is moved 1 cm proximally or distally to the injection site. Naloxone given systemically reverses this peripheral analgesia. Antisense oligodeoxynucleotides directed against exons 1 and 4 of MOR-1, a cloned mu opioid receptor, administered intrathecally (i.t.) block the local analgesic effect of morphine in the tail, indicating that the local response is mediated through mu receptors located on the terminals of sensory neurons from the dorsal root ganglia. Combinations of morphine given locally in the tail and spinally (i.t.) are synergistic. Spinal morphine also synergizes with systemic morphine in analgesia assays. Supraspinal morphine enhances systemic morphine analgesia, but less dramatically. We also examined tolerance on these analgesic systems by using a daily morphine injection paradigm which shifts the dose-response curve for systemic morphine approximately 2-fold after 5 days. In this paradigm, morphine's analgesic potency after either supraspinal or spinal administration alone does not change. However, the dose-response curve for local morphine in the tail is shifted by over 19-fold. The analgesic activity of the combination of supraspinal and systemic morphine is lowered approximately 2-fold and the combination of i.t. and systemic morphine by 12-fold. These studies confirm the presence of a peripheral mechanism for morphine analgesia mediated by mu receptors located on sensory neurons from the dorsal root ganglia, which is extremely sensitive to chronic morphine dosing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930151

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat.

Authors:  K O Aley; J D Levine
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

2.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

Review 3.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

4.  The central questions in pain perception may be peripheral.

Authors:  G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

5.  Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.

Authors:  Jin Xu; Andrew J Faskowitz; Grace C Rossi; Mingming Xu; Zhigang Lu; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

6.  Topical methadone and meperidine analgesic synergy in the mouse.

Authors:  Yuri A Kolesnikov; Galina Oksman; Gavril W Pasternak
Journal:  Eur J Pharmacol       Date:  2010-04-28       Impact factor: 4.432

Review 7.  Opiate pharmacology and relief of pain.

Authors:  Gavril W Pasternak
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

8.  Systemically and topically active antinociceptive neurotensin compounds.

Authors:  Grace C Rossi; Joshua E Matulonis; Elliott Richelson; Denise Barbut; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2010-06-24       Impact factor: 4.030

9.  Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.

Authors:  L J Sim-Selley; K L Scoggins; M P Cassidy; L A Smith; W L Dewey; F L Smith; D E Selley
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

10.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.